The history of Viagra and its effect on the pharmaceutical sector presents a intricate question regarding its continued viability as an investment. Initially a remarkable success, generating huge sums , generic competition has significantly eroded profit margins . While established pharmaceutical firms continue patents on related therapies and deve

The outlook of companies tied to flagship drugs like Viagra presents a nuanced investment picture. While the initial rise of copyright, fueled by Viagra's remarkable popularity, generated substantial wealth , the Adult patent expiration in key markets has introduced significant risk . Investors are now facing the consequences of generic competition